- Home
- OCX
as 12-18-2024 4:00pm EST
OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers.
| Founded: | 2009 | Country: | United States |
| Employees: | N/A | City: | IRVINE |
| Market Cap: | 38.7M | IPO Year: | N/A |
| Target Price: | $4.42 | AVG Volume (30 days): | 112.4K |
| Analyst Decision: | Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.04 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.98 - $3.82 | Next Earning Date: | 11-12-2024 |
| Revenue: | $709,000 | Revenue Growth: | -51.54% |
| Revenue Growth (this year): | -66.4% | Revenue Growth (next year): | 106.34% |
Stock Insider Trading Activity of Oncocyte Corporation (OCX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| BROADWOOD PARTNERS, L.P. | OCX | 10% Owner | Oct 2 '24 | Buy | $1.47 | 1,315,339 | $3,877,619.37 | 6,244,405 | |
| James Andrea S. | OCX | Chief Financial Officer | Oct 2 '24 | Buy | $2.97 | 33,670 | $99,999.90 | 33,670 |
Latest Oncocyte Corporation News
OCX Breaking Stock News: Dive into OCX Ticker-Specific Updates for Smart Investing
GlobeNewswire
9 days ago
Oncocyte to Participate in “J.P. Morgan Week” and Host Investor Meetings
GlobeNewswire
14 days ago
Oncocyte Demonstrates Potential for Liquid Biopsy of Brain Tumors in New Study
GlobeNewswire
16 days ago
Oncocyte dd-cfDNA Assay Detects Kidney Transplant Rejection 11+ Months Ahead of Standard Protocols, New Study Affirms
GuruFocus.com
a month ago
OncoCyte Corp (OCX) Q3 2024 Earnings Call Highlights: Progress in Transplant Testing and ...
GlobeNewswire
a month ago
Oncocyte Reports Commercial Launch Progress; On Track to Sign 20 Transplant Centers by End of 2025
GlobeNewswire
a month ago
Oncocyte To Announce Third Quarter 2024 Financial Results on Nov. 12
GlobeNewswire
2 months ago
Oncocyte Announces Participation in the LD Micro Main Event XVII Conference in Los Angeles
GlobeNewswire
2 months ago
Oncocyte’s DetermaIO Immuno-Oncology Assay Predicts Response to Atezolizumab in Phase 2 Clinical Trial
Compare OCX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "OCX Oncocyte Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.